A Phase IIa Study of JAB-8263 in Patients With Active Rheumatoid Arthritis

Starting soon · Phase 2

Conditions studied: Rheumatoid Arthritis (RA)

In brief

This study is an open-label, multi-center Phase IIa study. The study is divided into two phases. The first phase is a safety exploration phase. Participants with active rheumatoid arthritis were enrolled and treated with JAB-8263 alone for 4 weeks. The purpose is to evaluate the safety, PK/PD characteristics and preliminary effectiveness of JAB-8263 in participants with active RA.

Key facts

Study ID

NCT07684157

Run by

Jacobio Pharmaceuticals Co., Ltd.

People needed

32

Starts

2026-07-29

Expected to finish

2027-12-31

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years old and <75 years old at the time of signing the informed consent form, regardless of gender;
• Active rheumatoid arthritis, ESR or C-reactive protein> upper limit of normal
• Meets the 2010 American College of Rheumatology ACR/EULAR RA classification standards
• Participants have recovered from adverse reactions to previous antirheumatic treatment.

You may not qualify if…

• Use of topical glucocorticoids within 2 weeks before the first dose of investigational product or have received epidural, intraarticular, intramuscular, oral or intravenous glucocorticoids within 4 weeks, and do not use adrenocorticotropin;
• Use of NSAIDs within 1 week before first dose of investigational product
• Known or suspected allergies to the investigational product or any of its components;
• Current active shingles virus infection, including shingles or herpes simplex types 1 and 2 (confirmed by physical examination and medical history); participants had a history of severe herpes infection, including any disseminated disease, shingles in multiple skin areas, herpes encephalitis, ocular herpes, or recurrent shingles (2 episodes greater than or equal to 2 episodes within 2 years);
• Have evidence of active tuberculosis (TB) or have previously had evidence of active TB and have not received appropriate documented treatment;

Where it is running

• Beijing Hospital — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.